Kisqali 100mg

Kisqali 100 mg is used together with an aromatase inhibitor as an initial endocrine therapy for the treatment of postmenopausal patients with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer.

Treatment of breast cancer

It should be used in conjunction with an aromatase inhibitor (such as letrozole) as a primary endocrine-based treatment for postmenopausal patients with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer.
Kisqali comes in the form of pill for oral intake. The common dose of Kisqali is 600 mg (six 100 mg film-coated pills) taken by mouth, once a day for 3 consecutive weeks followed by a week off treatment, which results in a full cycle of 4 weeks.

The main active component of Kisqali 100 mg is called ribociclib. It impedes the activity of enzymes called cyclin-dependent kinases (CDK) 4 and 6, responsible for the growth and division of cells. By preventing the above-mentioned Kisqali 100 mg delays the progression of cancer cells.

This drug can be taken irrespective of the mealtime. In combination with letrozole, the dose is 2.5 mg once a day during the 4-week cycle. Carefully read the prescribing information of letrozole. For dosage and use with other medications, study the drug instructions. It is recommended to take the medications at the same time every day (better before breakfast).

If you experience vomiting after taking the drug, or skip the dose, don’t take it the same day. Just take the next dose in due time. Try to swallow the pill whole instead of chewing or crushing it.
The most widespread adverse effects of Kisqali (affecting about 20% of patients) are leukopenia, head pain, pain in the back, sickness and vomiting, loose bowels, blockage, exhaustion, hair loss and hives.

The most widespread serious adverse effects of Kisqali (affect about one out of fifty patients) are neutropenia, sickness and vomiting, weakness, pain in the back, liver problems and hypophosphataemia (serum phosphate concentration lower 2.5 mg/dL).

Kisqali 100 mg shouldn’t be taken by the patients who have allergy to any of its components, as well as soya or peanuts.